Target type: molecularfunction
Enables the transfer of a purine nucleoside, a purine base covalently bonded to a ribose or deoxyribose sugar, from one side of a membrane to the other. [GOC:ai]
Purine nucleoside transmembrane transporter activity is a fundamental process in cellular metabolism, facilitating the movement of purine nucleosides, such as adenosine, guanosine, and inosine, across cell membranes. These nucleosides play vital roles in various cellular functions, including DNA and RNA synthesis, energy production, signal transduction, and immune responses. The transport mechanism typically involves the binding of a purine nucleoside to a specific transporter protein embedded within the cell membrane. This binding triggers conformational changes in the transporter, allowing the nucleoside to pass through the membrane from one side to the other. The direction of transport can be either inward, bringing nucleosides into the cell, or outward, exporting them. The specific mechanism and regulation of purine nucleoside transport vary depending on the transporter protein and the cellular context. For instance, some transporters are highly selective for specific purine nucleosides, while others exhibit broader substrate specificity. Additionally, transport activity can be regulated by factors such as substrate concentration, pH, and the presence of inhibitors. The efficient transport of purine nucleosides is essential for maintaining cellular homeostasis and ensuring proper cellular function. Dysregulation of purine nucleoside transport can contribute to various disease states, including cancer, autoimmune disorders, and neurological disorders. Therefore, understanding the molecular mechanisms underlying purine nucleoside transport is crucial for developing novel therapeutic strategies for these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Equilibrative nucleoside transporter 1 | An equilibrative nucleoside transporter 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99808] | Homo sapiens (human) |
Equilibrative nucleoside transporter 2 | An equilibrative nucleoside transporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14542] | Homo sapiens (human) |
Sodium/nucleoside cotransporter 2 | A sodium/nucleoside cotransporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43868] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
dilazep | dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties. Dilazep: Coronary vasodilator with some antiarrhythmic activity. | benzoate ester; diazepane; diester; methoxybenzenes | cardioprotective agent; platelet aggregation inhibitor; vasodilator agent |
dipyridamole | dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent |
lidoflazine | Lidoflazine: Coronary vasodilator with some antiarrhythmic action. | diarylmethane | |
floxuridine | floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent |
uridine | uridines | drug metabolite; fundamental metabolite; human metabolite | |
phlorhizin | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | antioxidant; plant metabolite | |
methylthioinosine | Methylthioinosine: 6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. | purine ribonucleoside; thiopurine | |
hyaluronoglucosaminidase | kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source | purine nucleoside | |
gemcitabine | gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. | organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic |
draflazine | draflazine: a nucleoside transport inhibitor; has cardioprotective effect; draflazine is the (-)-enantiomer; R 88016 is the (+)-enantiomer | ||
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
4-nitrobenzylthioinosine | 4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1 | purine nucleoside | |
n(6)-benzyladenosine | N(6)-benzyladenosine: RN given refers to parent cpd | ||
6-(4-nitrobenzylthio)guanosine | 6-(4-nitrobenzylthio)guanosine: inhibitor of nucleoside transport | ||
5-iodotubercidin | 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase | organoiodine compound | |
n(6)-phenyladenosine | purine nucleoside | ||
tecadenoson | tecadenoson: an A1 adenosine receptor agonist | ||
2-hydroxy-5-nitrobenzylthioguanosine | |||
n(6)-cyclopentyladenosine | |||
7,8,3'-trihydroxyflavone | 7,8,3'-trihydroxyflavone: a potent small molecule TrkB receptor agonist that protects spiral ganglion neurons from degeneration both in vitro and in vivo | ||
6-benzylthioinosine | 6-benzylthioinosine: a subversive substrate of T gondii adenosine kinase; structure in first source |